MedPath

A study to compare conventional salvage radiotherapy and individualized treatment based on results from PSMA PET/CT assessments in patients with recurrence after prostate cancer surgery

Phase 1
Conditions
Biochemical recurrence after prostate cancer surgery
MedDRA version: 21.0Level: PTClassification code: 10036911Term: Prostate cancer recurrent Class: 100000004864
Therapeutic area: Diseases [C] - Neoplasms [C04]
Registration Number
CTIS2023-504917-54-00
Lead Sponsor
Karolinska University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Male
Target Recruitment
450
Inclusion Criteria

Patients previously treated for prostate cancer with radical prostatectomy and now having a biochemical recurrence (BCR) defined as: PSA >0.2 <2.0 ng/mL, and increasing measured twice., Multidisciplinary conference (MDK) decision to offer the patient salvage radiotherapy (SRT)., Signed Informed Consent

Exclusion Criteria

Previous prostate cancer with biochemical recurrence, Previous treatment with ADT after surgery, Previous pelvic radiotherapy, Patients with positive lymph nodes at surgery

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath